Following a bumpy regulatory road that involved a refusal-to-file, ImmunityBio has won FDA approval to expand Anktiva into ...
Hot off a pair of key FDA green lights this summer, rare disease specialist Ultragenyx has wasted little time cashing in a ...
With a yearslong patent dispute between the two drugmakers finally put to bed—complete with a hefty settlement payout—United ...
Expanding its presence in dermatology, Cetaphil maker Galderma has agreed to acquire professional skincare shop Zo Skin ...
Seizing that momentum these past two weeks were Prolific Machines—aiming optogenetics at current biomanufacturing ...
Sanofi has avoided a European Union fine after antitrust regulators accepted its commitments to address the alleged ...
Martin Shkreli is back in the Federal Trade Commission’s spotlight, this time for allegedly violating his l | The FTC alleges ...
Shares of Syndax Pharmaceuticals have tumbled 17% after a phase 2 flop | Syndax and Incyte are cutting their idiopathic ...
The U.S. Court of Appeals for the Third Circuit has rejected an IRA price negotiation lawsuit from Novartis, seven days after doing the same on an appeal from Bristol Myers Squibb and Johnson & ...
Since the drug’s approval and launch earlier this year, J&J has recorded more than 20,000 patient starts on Icotyde, funneled ...
UCB is encouraging people with immunology-driven diseases such as hidradenitis suppurativa (HS), plaque psoriasis and ...
Rather than another instance of on-shoring enthusiasm, ARPA-H’s personalized RNA drug production network project should be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results